59 Pancreatic ductal adenocarcinoma (PDAC), the most common type of pancreatic cancer, remains one of the deadliest malignancies due to its late detection. But a new wave of research focusing on liquid biopsies – minimally invasive blood tests – offers a potential breakthrough in diagnosing this silent killer at earlier stages. The findings were published in the Journal of Experiental & Clinical Cancer Research. PDAC is often diagnosed in advanced stages because early symptoms are either absent or non-specific. Current imaging techniques, while valuable, have limitations, including cost, time inefficiency, and exposure to radiation. Additionally, only a minority of patients are eligible for curative surgery upon diagnosis. These challenges underscore the urgent need for alternative diagnostic methods. Liquid biopsy technology focuses on analysing tumour-derived components such as circulating tumour cells (CTCs), cell-free DNA (cfDNA), and extracellular vesicles (EVs) found in bodily fluids like blood. These biomarkers can reveal the presence of cancer, track its progression, and even provide insights into its molecular characteristics. Among these, the use of multibiomarker panels—combinations of different biomarkers—has shown promise in improving diagnostic accuracy. Single biomarkers, such as carbohydrate antigen 19-9 (CA19-9), have long been used to monitor pancreatic cancer. However, their utility is limited, especially for early detection, due to low specificity and sensitivity. Factors like genetic variations among patients can also lead to false negatives. By contrast, combining biomarkers into panels enhances diagnostic performance, offering higher sensitivity and specificity. Recent studies have explored various biomarker combinations. For example, adding CA19-9 to a panel of proteins such as TIMP1 and LRG1 significantly improved diagnostic accuracy. Similarly, panels incorporating EV-derived proteins and RNAs have demonstrated potential, particularly in identifying early-stage PDAC. In one study, an EV-based protein panel achieved a sensitivity of 90% and a specificity of 94% in detecting early-stage cases. Circulating DNA analysis has also gained traction. Tumour-derived cfDNA can be identified through mutations, methylation patterns, and fragmentomic features. Research has shown that ctDNA analysis can pinpoint key genetic mutations associated with PDAC, such as alterations in KRAS, CDKN2A, TP53, and SMAD4. Although ctDNA’s presence is often minimal in early stages, advances in detection methods are helping to overcome these hurdles. Despite these strides, challenges remain. The heterogeneity of PDAC tumours complicates the development of universally reliable panels. Additionally, the limited availability of validated clinical assays slows the transition of these technologies from research to routine practice. Cost and accessibility also remain barriers, particularly for widespread screening efforts. Nevertheless, the potential of liquid biopsies to transform pancreatic cancer diagnosis cannot be overstated. By enabling earlier detection, these tools could significantly improve survival rates. Researchers continue to refine biomarker panels, integrating insights from genetics, proteomics, and epigenetics to build more robust diagnostic systems. The future of PDAC diagnosis lies in the collaborative efforts of scientists, clinicians, and industry stakeholders to address current limitations. With continued investment and innovation, liquid biopsy could become a standard tool in the fight against pancreatic cancer.